Shots:

• Boston currently holds ~16% equity stake in Devor & acquires the remaining 84% for ~$269M up front and ~$67M upon achievement of clinical & regulatory milestones. The transaction is expected to close in Q4’21
• The acquisition will advance the peripheral interventions portfolio with the addition of Devoro’s WOLF thrombectomy platform to improve procedural efficiencies & removes blot clots
• The WOLF technology is designed to targets & capture blood using finger-like prongs that repair and remove thrombi in the arterial and venous systems without damaging blood vessels

Ref: Boston Scientific | Image: MDDI